Applied DNA to Present Advanced DNA Platforms at World Vaccine Congress

Applied DNA Sciences, Inc. (NASDAQ:APDN), recognized for its PCR-based DNA technologies, is set to feature its Linea™ IVT and Linea™ DNA platforms at the 24th Annual World Vaccine Congress, taking place from April 1 to 4, 2024, in Washington D.C. The event will provide an opportunity for one-on-one meetings with Applied DNA sales team members at the Walter E. Washington Convention Center.

The Linea DNA platform stands out for its cell-free DNA production capability, deriving from Applied DNA's extensive experience in the enzymatic production of DNA. This platform can produce DNA in a range from milligrams to grams and supports the creation of high-fidelity DNA constructs between 100bp and 20kb in size. Notably, DNA produced through this platform does not contain adventitious DNA sequences found in other sources and is advantageously scalable and modifiable.

Furthermore, the Linea IVT platform integrates DNA IVT templates produced by the Linea DNA platform with a proprietary Linea™ RNAP, offering advancements in mRNA and sa-mRNA production. Applied DNA believes this to lead to improved mRNA production speeds and quality, by removing plasmid DNA from the initial stages, diminishing dsRNA contamination, and streamlining production workflows.